Bio-Techne Announces Release of Lateral Flow Technology Proof of Concept Data
MINNEAPOLIS, December 8, 2021 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced the publication of an important manuscript in the journal Scientific reports, a journal from Nature Research, showing the proof of concept of its proprietary lateral flow technology. The manuscript is titled SARS-CoV-2 Antigen Rapid Diagnostic Test for Resource-Limited Settings. In this manuscript, Bio-Techne scientists demonstrate a method to develop an inexpensive alternative test to diagnose active COVID-19 infection caused by SARS-CoV-2 with a minimally invasive anterior nostril swab specimen.
The article discusses a proof-of-concept lateral flow-based test that identifies the presence of the SARS-CoV-2 antigen with no equipment or laboratory infrastructure to administer. The test produces results quickly after 15 minutes with a detection limit of 2.0 x 102 TCID50/mL, 87.5% sensitivity and 100% specificity.
“This manuscript clearly demonstrates the power of our proprietary lateral flow technology,” said chuck kummeth, President and CEO. “We look forward to leveraging this technology while supporting our OEM partnerships in the future.”
Bio-Techne intends to use its extensive collection of proteins, antibodies and technologies to partner with diagnostic companies to develop additional rapid diagnostic tests and to offer design and development services. custom development for lateral flow assay reagents, test development and manufacturing.
This is the second publication on Bio-Techne’s lateral flow initiatives this year, following the first article titled “Use of Lateral Flow Immunoassay to Characterize SARS-CoV-2 RBD Specific Antibodies and Their Ability to React with UK, SA, and BR P.1 Variant RBDs” published in the journal of Diagnostic2021, 11, 1190. This article demonstrated that the lateral flow immunoassay could be a rapid and efficient tool for antibody characterization, including epitope classification and neutralization kinetics of surrogate antibodies.
About Bio-Techne Corporation (NASDAQ:TECH)
Contact: David ClaireSenior Director, Investor Relations and Corporate Development
[email protected]
612-656-4416
SOURCE Bio-Techne Corporation
